STOCK TITAN

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its participation in the Jefferies London Global Healthcare Conference. CEO Mike Exton will join a moderated discussion on Wednesday, November 20, 2024, at 9:00 am GT. The event will be accessible via live webcast in the 'Events' section of Lexicon's website, with the recording remaining available for two weeks after the original broadcast.

Lexicon Pharmaceuticals (Nasdaq: LXRX) ha annunciato la sua partecipazione alla Conferenza Globale sulla Salute di Jefferies a Londra. Il CEO Mike Exton parteciperà a una discussione moderata mercoledì 20 novembre 2024, alle 9:00 ora di Greenwich. L'evento sarà accessibile tramite webcast dal vivo nella sezione 'Eventi' del sito web di Lexicon, con la registrazione disponibile per due settimane dopo la trasmissione originale.

Lexicon Pharmaceuticals (Nasdaq: LXRX) ha anunciado su participación en la Conferencia Global de Salud de Jefferies en Londres. El CEO Mike Exton se unirá a una discusión moderada el miércoles 20 de noviembre de 2024, a las 9:00 a.m. hora de Greenwich. El evento será accesible a través de una transmisión en vivo en la sección 'Eventos' del sitio web de Lexicon, con la grabación disponible durante dos semanas después de la transmisión original.

Lexicon Pharmaceuticals (Nasdaq: LXRX)는 제퍼리스 런던 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO 마이크 엑스턴이 2024년 11월 20일 수요일 오전 9시(그리니치 시간)에 진행되는 패널 토론에 참석할 예정입니다. 이 행사는 Lexicon 웹사이트의 '이벤트' 섹션에서 라이브 웹캐스트로 시청할 수 있으며, 원래 방송 이후 2주 동안 녹화본이 제공됩니다.

Lexicon Pharmaceuticals (Nasdaq: LXRX) a annoncé sa participation à la Conférence Mondiale sur la Santé de Jefferies à Londres. Le PDG Mike Exton participera à une discussion modérée le mercredi 20 novembre 2024, à 9h00 GMT. L'événement sera accessible via un webcast en direct dans la section 'Événements' du site web de Lexicon, avec l'enregistrement restant disponible pendant deux semaines après la diffusion originale.

Lexicon Pharmaceuticals (Nasdaq: LXRX) hat seine Teilnahme an der Jefferies London Global Healthcare Conference bekannt gegeben. CEO Mike Exton wird am Mittwoch, den 20. November 2024, um 9:00 Uhr GMT an einer moderierten Diskussion teilnehmen. Die Veranstaltung wird über einen Live-Stream im Bereich 'Veranstaltungen' auf der Website von Lexicon zugänglich sein, wobei die Aufzeichnung zwei Wochen nach der ursprünglichen Übertragung verfügbar bleibt.

Positive
  • None.
Negative
  • None.

THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference. Lexicon management including Mike Exton, Lexicon’s chief executive officer and director will participate in a moderated discussion on Wednesday, November 20, 2024, at 9:00 am GT.

A simultaneous webcast will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events, and a recording of the webcast will be available for two weeks following the original on-demand date.

About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has commercially launched one of these medicines, INPEFA® (sotagliflozin) in the United States, and has a pipeline of other promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement 

This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize INPEFA in heart failure on the timeline and/or at the prices currently contemplated or at all, conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin (in other indications), LX9211, LX9851 and its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2023 and other subsequent disclosure documents filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. 

For Investor and Media Inquiries:

Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.        
lexinvest@lexpharma.com


FAQ

When is Lexicon Pharmaceuticals (LXRX) presenting at the Jefferies London Healthcare Conference 2024?

Lexicon Pharmaceuticals (LXRX) will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 9:00 am GT.

How can I watch Lexicon Pharmaceuticals' (LXRX) presentation at the Jefferies Conference?

You can watch the presentation via live webcast in the 'Events' section of Lexicon's website at www.lexpharma.com/events. A recording will be available for two weeks afterward.

Who will represent Lexicon Pharmaceuticals (LXRX) at the 2024 Jefferies London Healthcare Conference?

Mike Exton, Lexicon's chief executive officer and director, will represent the company in a moderated discussion at the conference.

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

LXRX Rankings

LXRX Latest News

LXRX Stock Data

437.41M
361.49M
1.15%
79.32%
7.65%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
THE WOODLANDS